Alnylam Pharmaceuticals continues to lead in RNAi therapeutics with a standout quarter!

Written By Kimberly Hicks

https://www.businesswire.com/news/home/20250731812786/en/Alnylam-Pharmaceuticals-Reports-Second-Quarter-2025-Financial-Results-and-Highlights-Recent-Period-Progress

Kimberly Hicks
Previous

argenx Delivers Strong First Half Performance!
Next

Apellis Pharmaceuticals receives FDA approval of EMPAVELI® (pegcetacoplan)